#China #Suzhou #Porton Advanced #Drug Manufacturing #CGT Solutions

Expanding Horizons in Gene and Cell Therapy Manufacturing

Porton Advanced Solutions Ltd. has recently marked a significant achievement by securing a Class C Drug Manufacturing License from the National Medical Products Administration (NMPA). This development positions Porton Advanced to enhance its contract development and manufacturing organization (CDMO) services, specifically in the realm of cell and gene therapy (CGT) products. As the demand for effective therapies in this sector continues to grow, Porton Advanced is primed to meet the challenge with expanded capabilities in manufacturing and quality assurance.

Transitioning to Commercial Production

The newly acquired Class C license allows Porton Advanced to officially engage in commercial-scale manufacturing projects at its state-of-the-art facilities in China. These facilities recently passed stringent regulatory inspections, thus confirming their compliance with Good Manufacturing Practices (GMP), which is essential for the production of high-standard medical products.

With over 20,000 square meters dedicated to research and development as well as manufacturing, Porton Advanced boasts ten viral vector production lines and twelve GMP-certified cell therapy suites. This infrastructure transitions the company's operations from merely supporting research and clinical trial preparations to achieving a fully commercial-ready status.

Robust Quality Management Systems

Porton Advanced has invested significantly in establishing a quality management system that meets international standards set by regulatory bodies such as the NMPA, the U.S. FDA, and the European Medicines Agency (EMA). This commitment to quality ensures that all projects executed under its brand adhere to the highest standards, leading to an impressive 100% success rate in submitting Investigational New Drug (IND) applications.

Comprehensive Services Across CGT Product Lifecycle

In alignment with its mission to facilitate earlier access to effective medications, the Class C license affirms Porton Advanced's commitment to providing end-to-end CDMO services. This includes an extensive range of CGT products, such as plasmids, lentiviruses, CAR-T therapies, and exosomes, covering the complete spectrum from clinical trials to commercialization.

One of the primary advantages of partnering with Porton Advanced lies in its capability to reduce costs and risks associated with technological transfers and scaling up production. Given the intricate nature of CGT products, having a reliable partner like Porton Advanced can greatly streamline the transition from lab to clinic.

Strengthening Client Partnerships

Porton Advanced has rapidly expanded its clientele, currently serving over 200 customers worldwide. The company is proud to have facilitated 26 global IND approvals, including the groundbreaking in vivo CAR-T therapy in China. Additionally, it has gained valuable experience managing 12 programs in various stages, from Phase I and II trials to commercial-scale production.

As a testament to its capabilities, Porton Advanced is currently engaged in a cell therapy project that is approaching its Biologics License Application (BLA) submission—a critical step in bringing innovative therapies to market.

Impacting Patient Accessibility to CGT Therapies

The establishment of commercial-scale manufacturing capabilities is crucial for ensuring a consistent supply of CGT drugs, transforming them from lab projects to accessible treatments for patients. Porton Advanced is dedicated to creating a compliant and stable commercial supply framework, which aims to alleviate pricing pressures that have historically plagued these advanced therapies due to production limitations.

Andrew Chen, the CEO of Porton Advanced, emphasized, "Achieving the Class C Drug Manufacturing License is a transformative milestone for our company. It validates our quality systems and our dedication to partnering effectively with our clients during product launches. Moving forward, we will continue to prioritize our clients’ needs and leverage our operational excellence to ensure that advanced therapies reach patients safely and efficiently."

Future Goals and Commitment

Looking ahead, Porton Advanced remains committed to enhancing its CGT CDMO services, offering comprehensive solutions throughout the entire drug development continuum—from process development and IND filing to clinical production and commercial manufacturing. The overarching goal is to accelerate the clinical application of CGT products and extend their benefits to patients globally.

About Porton Advanced Solutions

As a vital subsidiary of Porton Pharma Solutions, Porton Advanced Solutions maintains its headquarters in Cranbury, New Jersey, alongside two GMP-certified facilities in Suzhou, China. The company specializes in delivering end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs). From initial research to IND applications and commercialization, Porton Advanced supports its clients with expertise and quality-driven services designed to facilitate earlier access to effective medicines.